1-[3-[3-[4-(5,6-dimethoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indol-5-yl]-N-methylmethanesulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-[3-[3-[4-(5,6-dimethoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
• 化学式: C₂₃H₃₂N₆O₄S
• 分子量: 488.6
• InChiKey: JGXPMHZKNOUBAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF MIGRAINE, COMPOSITION AND UTILIZATION
  申请人：VITA-INVEST, S.A.

  公开号：EP0714896A1

  公开（公告）日：1996-06-05

  Indole derivatives having the Formula (I) wherein R₁ is H, alkyl or acyl group; R₂ is H, halogen or alkyl, hydroxy, alkoxy; ciano, carboxamide, carboxyl, alkoxicarbonyl, phenyl, phenyloxy or a group -(CH₂)n-R₆, (n=1-3), and R₆ is a group ciano, nitro, phenyl, carboxyl, -CO₂R₇; -CONR₇R₈; -SO₂NR₇R₈; -COR₇; -SO₂R₇, R₇ and R₈ being H or alkyl; R₇ and R₈, together with N, can form a cycle of 4-7 links; R₃, R₄ and R₅ are H, halogen or a group alkyl, phenyl, substituted phenyl, hydroxy, alcoxy, phenyloxy or benziloxy; NR₁₁R₁₂ is H or a group ciano, nitro, carboxyl, alcoxycarbonyl, carboxamido or a group R₃; A is an alkyliden group -(CH₂)-m, (m = 1-5), or alkenyl group; B is a piperazinoring (a), aminopyrrolidinoring (b); pyrrolidinamino ring (c); piperidinoring (d) or ethylendiamino -NR₉-CH₂-CH₂-NR₁₀-, R₉ and R₁₀ being H or an alkyl group. The compounds are useful for the treatment of migraine.

  吲哚衍生物具有以下式（I）其中R₁为H、烷基或酰基；R₂为H、卤素或烷基、羟基、烷氧基；氰基、羧酰胺基、羧基、烷氧基羰基、苯基、苯氧基或一个基团-(CH₂)n-R₆，（n=1-3），且R₆为一个基团氰基、硝基、苯基、羧基、-CO₂R₇；-CONR₇R₈；-SO₂NR₇R₈；-COR₇；-SO₂R₇，R₇和R₈为H或烷基；R₇和R₈，与N一起，可形成一个4-7个连接的环；R₃、R₄和R₅为H、卤素或一个烷基、苯基、取代苯基、羟基、烷氧基、苯氧基或苄氧基基团；NR₁₁R₁₂为H或一个基团氰基、硝基、羧基、烷氧羰基、羧酰胺基或一个基团R₃；A为一个烷基亚甲基基团-(CH₂)-m，（m=1-5），或烯基基团；B为哌嗪环（a）、氨基吡咯啉环（b）；吡咯啉氨基环（c）；哌啶环（d）或乙二胺-NR₉-CH₂-CH₂-NR₁₀-，R₉和R₁₀为H或一个烷基基团。这些化合物可用于治疗偏头痛。
• Fast-dispersing dosage form containing 5-HT1 agonists
  申请人：——

  公开号：US20040023948A1

  公开（公告）日：2004-02-05

  This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HT 1 agonist, characterized in that the composition is formulated to reduce pre-systemic metabolism of said 5-HT 1 agonist. A process for preparing such a composition and the use of such a composition for the treatment of anxiety, depression, attention deficit disorder and/or panic disorders and/or as a memory enhancer are also provided.

  本发明涉及一种口服药物组合物，该组合物由载体和作为活性成分的 5-HT 1 激动剂，其特征在于该组合物的配制可减少所述 5-HT 1 激动剂。本发明还提供了制备这种组合物的工艺以及这种组合物用于治疗焦虑症、抑郁症、注意力缺陷障碍和/或恐慌症和/或作为记忆增强剂的用途。
• PHARMACEUTICAL COMPOSITION
  申请人：R.P. Scherer Limited

  公开号：EP0969842A1

  公开（公告）日：2000-01-12
• [EN] PHARMACEUTICAL COMPOSITION<br/>[FR] COMPOSITION PHARMACEUTIQUE
  申请人：R. P. SCHERER LIMITED

  公开号：WO1998042344A1

  公开（公告）日：1998-10-01

  (EN) This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HT1 agonist, characterised in that the composition is formulated to reduce pre-systemic metabolism of said 5-HT1 agonist. A process for preparing such a composition and the use of such a composition for the treatment of anxiety, depression, attention deficit disorder and/or panic disorders and/or as a memory enhancer are also provided.(FR) L'invention concerne une composition pharmaceutique administrable par voie orale, qui comprend un vecteur et, comme principe actif, un agoniste 5-HT1. Ladite composition se caractérise par une formulation propre à réduire le métabolisme pré-systémique dudit agoniste 5-HT1. L'invention concerne en outre une méthode de préparation et d'utilisation de ladite composition pour le traitement de l'anxiété, de la dépression, du trouble déficitaire de l'attention et/ou du trouble panique, et/ou comme stimulant de la mémoire.